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Summary
Background.  —  Chronic  heart  failure  (CHF)  is  a  frequent  severe  disease.  Disease-management
programmes,  which  contain  a  therapeutic  patient  education  component,  will  play  a  central  role
in improving  delivery  of  care  and  reducing  mortality  and  hospitalizations  for  CHF.
Aims. —  In  order  to  have  an  up-to-date  overview  of  medical  treatment  of  CHF  in  France  imple-
mented by  hospital  and  clinic  cardiologists  especially  interested  in  CHF  and  therapeutic  patient
education,  we  described  the  prescription  of  cardiovascular  drugs  in  the  large  ODIN  cohort  of
CHF patients,  according  to  age  and  type  of  CHF.
Methods.  —  From  2007  to  2010  (median  follow-up  27.2  months),  CHF  patients  were  prospec-
tively enrolled  in  a  multicentre  ‘real-world’  French  cohort  by  centres  previously  trained
in therapeutic  patient  education.  Patients  were  grouped  according  to  age  (<  60  years,  60
to <  70  years,  70  to  <  80  years  and  ≥  80  years)  and  type  of  CHF  (characterized  by  level  of  LVEF:
reduced,  borderline  or  preserved).  Medical  prescription  was  described  and  mortality  was
assessed at  long-term  follow-up.
Results.  —  The  cohort  consisted  of  3237  patients  (67.6  years;  69.4%  men).  The  oldest  age  group
had the  highest  LVEF.  Blockers  of  the  angiotensin-aldosterone  system  were  prescribed  pro-
gressively and  signiﬁcantly  less  frequently  as  the  population  advanced  in  age  or  as  LVEF  was
more preserved.  The  mean  dosages  of  the  main  prescribed  CHF  drugs  remained  ≥  50%  lower
than those  recommended  for  most  drugs  in  all  age  and  LVEF  groups.  Drug  prescriptions  were
related to  aetiology  of  reduced  or  preserved  CHF.  A  global  decrease  in  CHF  drug  prescription
was observed  for  all  medication  classes  except  calcium  blockers,  according  to  maintenance  of
relatively or  totally  preserved  LVEF.  Survival  was  related  to  age  but  not  to  type  of  CHF.
Conclusion.  —  In  CHF,  and  despite  management  by  cardiologists  particularly  interested  in  CHF
and speciﬁcally  trained  to  deliver  therapeutic  patient  education,  medical  prescription  differed
substantially  from  guidelines.  Age  and  type  of  CHF  (reduced  versus  preserved)  appeared  to  be
important factors  in  lack  of  adherence  to  guidelines.  However,  only  age  inﬂuenced  mortality;
the type  of  CHF  did  not  affect  survival.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’insufﬁsance  cardiaque  (IC)  est  une  maladie  fréquente  et  sévère.  Les  programmes
de prise  en  charge  de  la  maladie,  qui  contiennent  une  composante  d’éducation  thérapeutique
du patient,  jouent  un  rôle  central  dans  l’amélioration  des  soins  et  la  réduction  de  la  mortalité
et des  hospitalisations  liées  à  l’IC.
Objectif.  — Aﬁn  d’avoir  un  aperc¸u  récent  du  traitement  médical  de  l’IC  en  France,  mis  en  place
par des  cardiologues  d’hôpitaux  ou  de  cliniques  spécialement  intéressés  par  l’IC  et  l’éducation
thérapeutique  du  patient,  nous  avons  décrit  la  prescription  des  médicaments  cardiovasculaires
au sein  de  la  grande  cohorte  ODIN  de  patients  IC  selon  l’âge  et  le  type  d’IC  déterminé  par  le
niveau de  fraction  d’éjection  ventriculaire  gauche  (FEVG).
Méthodes.  —  De  2007  à  2010  (suivi  médian  27,2  mois),  les  patients  IC  étaient  prospectivement
inclus dans  une  cohorte  franc¸aise  multicentrique  sur  la  base  de  la  pratique  réelle,  par  des
centres ayant  été  formés  à  l’éducation  thérapeutique  du  patient.  Les  patients  étaient  regroupés
selon leur  âge  (<  60  ans  ;  60  à  <  70  ans  ;  70  à  <  80  ans  ;  et  ≥  80  ans)  et  le  type  d’IC  caractérisé  par
le niveau  de  FEVG  (réduite,  borderline  ou  préservée).  La  prescription  médicale  était  décrite  et
la mortalité  était  évaluée  à  long  terme.
Résultats.  —  La  cohorte  comprenait  3237  patients  (67,5  ans  ;  69,5%  d’hommes).  Le  groupe  d’âge
le plus  âgé  avait  la  FEVG  la  plus  haute.  Les  bloqueurs  du  système  angiotensine-aldostérone
étaient  progressivement  et  signiﬁcativement  moins  prescrits  alors  que  la  population  avanc¸ait
en âge  ou  que  la  FEVG  était  plus  préservée.  Le  dosage  moyen  des  drogues  principalement
prescrites  dans  l’IC  restait  au  moins  50  %  plus  bas  que  celui  recommandé  pour  la  majorité  des
substances  dans  tous  les  groupes  d’âge  ou  de  FEVG.  La  prescription  des  médicaments  était  liée
à l’étiologie  de  l’IC  avec  FEVG  réduite  ou  préservée.  Une  diminution  globale  de  la  prescription
des médicaments  de  l’IC  était  observée  en  fonction  du  maintien  d’une  FEVG  relativement  ou
totalement  préservée,  pour  toutes  les  classes  de  médicaments  à  l’exception  des  inhibiteurs
calciques.  La  survie  était  liée  à  l’âge  mais  pas  au  type  d’IC.
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Conclusions.  —  Dans  l’IC  et  malgré  une  prise  en  charge  par  des  cardiologues  particulière-
ment intéressés  à  l’IC  et  spéciﬁquement  formés  pour  pratiquer  une  éducation  thérapeutique
du patient,  la  prescription  médicale  différait  sensiblement  des  recommandations.  L’âge  et
le type  d’IC  (systolique  vs  à  fonction  systolique  préservée)  étaient  d’importants  facteurs
d’inadéquation  à  la  prescription  médicale  recommandée.  Cependant,  seul  l’âge  inﬂuenc¸ait
la mortalité;  le  type  d’IC  déﬁni  par  le  niveau  de  FEVG  ne  jouait  aucun  rôle  dans  la  survie.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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eIntroduction
Chronic  heart  failure  (CHF)  is  a  frequent  severe  disease  that
has  become  a  major  public  health  problem  in  industrial-
ized  countries  [1,2].  In  this  context,  disease  management
programmes  appear  geared  up  to  play  a  central  role  in
improving  delivery  of  care  [3,4]  and  reducing  mortality  and
CHF  hospitalizations,  as  established  by  meta-analyses  [5,6].
As  an  integral  part  of  disease  management  programmes,
therapeutic  patient  education  [7]  has  been  recognized  in
most  industrialized  countries  [4,8—10]  and  is  recommended
in  European  guidelines  [11].  Following  this  format,  the
insufﬁsance  cardiaque  :  éducation  thérapeutique  (I-CARE)
programme  was  developed  in  France  to  promote  the  estab-
lishment  of  therapeutic  patient  education  units  in  all  types
of  cardiology  centres,  based  on  a  voluntary  approach  by  the
medical  team  [12].  A  large  prospective  multicentre  French
cohort  of  CHF  patients  (ODIN:  observatoire  de  l’insufﬁsance
cardiaque)  enrolled  in  I-CARE  centres  trained  in  therapeu-
tic  patient  education  for  CHF  was  constituted  from  2007
to  2010  to  assess  the  role  of  therapeutic  patient  education
applied  in  routine  practice;  therapeutic  patient  education
by  trained  health  professionals  appeared  to  be  associated
with  a  decrease  in  all-cause  mortality  [13].  Among  multivari-
able  independent  prognostic  factors  of  survival,  younger  age
and  prescription  of  recommended  neurohormonal  blockers
appeared  to  play  an  important  role.
In  order  to  have  an  up-to-date  overview  of  medical  treat-
ment  of  CHF  in  France  implemented  by  hospital  and  clinic
cardiologists  especially  interested  by  CHF  and  trained  in
therapeutic  patient  education,  we  decided  to  describe  the
prescription  of  cardiovascular  drugs  in  the  large  ODIN  cohort
of  CHF  patients,  according  to  age  and  type  of  CHF.
Methods
Patient population
Selection  of  centres  has  been  described  in  detail  previously
[13].  Brieﬂy,  centres  had  to  have  fulﬁlled  the  requirements
for  participation  in  the  I-CARE  programme  [14],  thereby  val-
idating  their  specialization  in  CHF  management.  Training
was  completed  for  110  centres  in  2007  and  for  more  than
220  in  2010.  Among  the  ﬁrst  110  trained  centres  throughout
France,  61  (55.5%)  volunteered  to  contribute  patients  to  the
ODIN  cohort.Patients  were  enrolled  prospectively  between  2007  and
2010;  during  this  period  the  therapeutic  guidelines  for  CHF
remained  largely  stable  [11].  Enrolment  in  the  study  was
d
consecutive.  To  increase  the  external  validity,  exclusion
riteria  were  deliberately  kept  to  a  minimum:  patients  were
xcluded  only  if  they  attended  sites  not  participating  in  the
-CARE  programme  or  if  they  declined  to  participate.
All  patients  received  usual  care,  which  consisted  of  care
anagement  according  to  European  guidelines  [11].  Medical
herapy  was  adjusted  as  judged  necessary  by  the  investiga-
or.  Patients  completed  a  full  education  programme  [13,14]
n  addition  to  receiving  usual  care.
Four  patient  groups  were  deﬁned  according  to  age:
 60  years  (Age  1);  60  to  <  70  years  (Age  2);  70  to  <  80  years
Age  3);  and  ≥  80  years  (Age  4).
The  initial  clinical  questionnaire  did  not  take  into  account
he  pathophysiological  type  of  CHF  (i.e.  systolic  or  diastolic
HF);  however,  left  ventricular  ejection  fraction  (LVEF)  was
vailable  in  92.3%  of  the  patients,  with  a  mean  value  of
9.8  ±  14.2%  (range  6—88%).  The  threshold  for  deﬁning  LVEF
roups  has  been  discussed  in  European  and  American  heart
ailure  guidelines  [15,16]. We  chose  the  usual  45%  thresh-
ld  for  deﬁning  reduced  LVEF  and  the  50%  threshold  for
eﬁning  preserved  LVEF.  In  accordance  with  the  American
uidelines  [16],  we  preferred  to  create  a  borderline  group
o  see  if  patients  with  an  LVEF  between  45  and  50%  pre-
ented  a  similar  proﬁle  to  one  of  the  other  usual  LVEF  groups.
t  was  therefore  decided  to  create  three  groups  according
o  LVEF:  <  45%  (heart  failure  with  reduced  ejection  fraction,
F-REF);  45—50%  (heart  failure  with  borderline  ejection
raction,  HF-BEF);  and  >  50%  (heart  failure  with  preserved
jection  fraction,  HF-PEF).
ata collection
he  investigation  conformed  to  the  principles  outlined  in
he  Declaration  of  Helsinki.  The  study  was  approved  by  the
ommission  nationale  informatique  et  liberté  —  as  required
y  French  law  for  any  patient  cohort  study  in  France  —
nd  the  institutional  independent  ethical  committee  of  the
rench  Society  of  Cardiology.  All  patients  gave  informed
onsent  before  their  inclusion  in  the  cohort.  Declarations
f  inclusion  were  made  by  centres  on  both  nominative  1-
age  and  medical  2-page  record  forms  for  each  patient  after
eing  given  an  anonymous  number  by  the  centre;  these
ere  mailed  separately  to  the  French  Society  of  Cardiol-
gy.  Data  were  then  recorded  on  two  types  of  computerized
ase  record  forms  according  to  the  procedure  requested  and
pproved  by  the  Commission  nationale  informatique  et  lib-
rté.Data  were  collected  on  the  main  cardiovascular  classes  of
rugs  administered  by  the  oral  route:  all  recommended  CHF
lasses  (angiotensin-converting  enzyme  inhibitors  [ACEIs],
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eta-blockers,  angiotensin-receptor  blockers  [ARBs],  diuret-
cs,  mineralocorticoid-receptor  antagonists  [MRAs],  digoxin
nd  nitrates)  and  all  other  main  non-CHF  cardiovascular
lasses  usually  prescribed  for  the  treatment  of  CHF  causes  or
omplications  (amiodarone,  antiplatelet  therapies  [aspirin
nd  clopidogrel],  anticoagulant  drugs  [antivitamin  K  thera-
ies  only],  calcium  blockers  and  statins).  Furthermore,  for
ll  main  CHF  classes,  the  types  of  drugs  used  most  fre-
uently  were  listed  with  their  daily  dosage  (perindopril  and
amipril  for  ACEIs;  bisoprolol,  carvedilol,  metoprolol  and
ebivolol  for  beta-blockers;  candesartan  and  valsartan  for
RBs;  furosemide  for  loop  diuretics;  and  eplerenone  and
pironolactone  for  MRAs)  [13].
Follow-up  data  were  collected  through  contact  with  the
ttending  physicians,  the  patients  or  their  families.  If  miss-
ng,  vital  status  was  assessed  from  the  registries  of  the
atients’  birthplaces.  Only  4.9%  (n  =  158)  of  patients  were
ost  to  follow-up.
tatistical analysis
ll  continuous  variables  are  described  as  means  ±  standard
eviations,  except  for  time  variables,  which  are  expressed
s  medians  [interquartile  ranges].  All  categorical  varia-
les  are  described  with  absolute  and  relative  frequency
istributions.  Comparisons  between  groups  used  one-way
nalysis  of  variance  and  unpaired  t  tests  for  continuous
ariables  and  2 tests  for  discrete  variables.  The  Bonferroni
est  was  used  for  comparisons  between  LVEF  groups.  Sur-
ival  curves  were  generated  by  the  Kaplan-Meier  method
nd  compared  with  log-rank  tests.  Prognostic  factors
or  mortality,  including  age-deﬁned  groups,  LVEF-deﬁned
roups,  risk  factors,  heart  failure  aetiology,  biological  varia-
les  and  main  CHF  drug  treatments,  were  analysed  with
ivariate  and  multivariable  Cox  models.  Biological  varia-
les  were  categorized  into  quartiles  for  serum  creatinine
<  9.5  mg/L;  9.5—11.5  mg/L;  >  11.5—15.0  mg/L;  >  15  mg/L)
r  divided  according  to  their  median  value  for  serum
lucose  (≤  and  >  0.99  g/L)  and  serum  haemoglobin  (≤
nd  >  13.0  g/L).  Serum  natriuretic  peptides  were  organized
s  non-decompensated  (deﬁned  as  B-type  natriuretic  pep-
ide  ≤  400  pg/mL  and/or  N-terminal  pro-B-type  natriuretic
eptide  ≤  450  pg/mL  if  the  patient  was  aged  <  50  years,
 900  pg/mL  if  aged  between  50  and  75  years  and
 1800  pg/mL  if  aged  >  75  years)  or  decompensated  levels.
or  multivariable  models,  a  stepwise  variable  selection  with
le  =  0.1  and  sls  =  0.05  was  applied.  Results  are  expressed  as
azard  ratios  with  a  95%  conﬁdence  interval.
All  statistical  analyses  were  performed  using  SPSS  version
ASW  18.0  software.  For  all  tests,  P  <  0.05  was  considered
igniﬁcant.
esults
ardiovascular medications in the whole
opulationhe  ODIN  population  has  been  detailed  previously  [13].  In
ummary,  a  total  of  3248  patients  were  included  in  the  ODIN
ohort,  11  of  whom  were  declared  twice  (i.e.  by  two  dif-
erent  centres).  For  these  patients,  the  ﬁrst  declaration
u
l
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as  considered  as  the  inclusion  in  the  cohort  and  the  sec-
nd  declaration  was  considered  as  a  follow-up  visit.  The
DIN  cohort  therefore  comprised  3237  patients  with  a  mean
ge  of  67.6  ±  14.2  years  (range  16—97  years);  69.4%  were
en.  Baseline  clinical  and  biological  main  variables  accord-
ng  to  age-deﬁned  and  LVEF-deﬁned  groups  are  reported  in
able  1.  For  CHF-dedicated  medications,  the  large  majority
f  patients  received  blockers  of  the  renin-angiotensin  sys-
em  (69.9%  received  ACEIs  and  20.3%  received  ARBs,  which
ere  always  prescribed  for  ACEI  intolerance),  beta-blockers
80.6%),  and  loop  diuretics  (80.1%).  Fewer  patients  were
reated  with  MRAs  (32.7%),  digoxin  (12.6%)  and  nitrates
8.7%).
Regarding  other  cardiovascular  medications,  20.4%  of  the
opulation  received  amiodarone,  40.8%  received  aspirin,
8.0%  received  clopidogrel,  43.3%  received  oral  anticoag-
lants,  8.8%  received  calcium  blockers  and  50.0%  received
tatins  [13].
Mean  duration  of  follow-up  was  25.9  ±  11.7  months.
eath  was  the  only  event  collected  during  follow-up;
82  deaths  were  recorded.  Multivariable  Cox  analysis  found
he  usual  predictors  of  survival  (Table  2).
ge and prescription of cardiovascular
edications
egarding  the  four  age-deﬁned  groups,  there  were  985
30.4%)  patients  in  Age  1,  669  (20.7%)  in  Age  2,  869  (26.8%)
n  Age  3  and  714  (22.1%)  in  Age  4.  The  percentage  of  men
ecreased  according  to  age  group  (74.1%  in  Age  1,  75.9%  in
ge  2,  70.2%  in  Age  3  and  56.0%  in  Age  4;  P  <  0.001).  Mean
VEF  was  signiﬁcantly  different  according  to  age  group:  the
lder  the  age  group,  the  higher  the  mean  LVEF  (36.0  ±  12.3%
or  Age  1,  38.3  ±  13.9%  for  Age  2,  41.2  ±  14.7%  for  Age
 and  44.8  ±  14.7%  for  Age  4;  P  <  0.001)  (Fig.  1).  Cumula-
ive  survival  curves  showed  the  effect  of  age  on  survival
Fig.  2).
The  three  major  CHF  medications  (ACEIs  +  ARBs,  beta-
lockers  and  MRAs)  were  prescribed  progressively  and
igniﬁcantly  less  frequently  as  the  population  advanced  in
ge  (Fig.  3).  By  comparison,  loop  diuretics,  digoxin  and
itrates  were  prescribed  more  frequently  with  advanc-
ng  age.  For  the  other  drugs,  prescriptions  were  probably
elated  to  aetiology  (antiplatelet  therapies,  statins  or
alcium  blockers)  or  the  presence  of  atrial  arrhythmias
amiodarone  and  anticoagulants)  (Fig.  3)  [13].
The  mean  dosages  of  the  main  prescribed  CHF  drugs
emained  ≥  50%  lower  than  those  recommended  for  the
ajority  of  the  drugs  (Table  3).  The  older  the  age,  the  lower
he  mean  dosage  (Table  3).
ype of CHF and prescription of
ardiovascular medications
egarding  the  three  LVEF-deﬁned  groups,  there  were  1934
59.7%)  patients  in  HF-REF,  460  (14.2%)  patients  in  HF-BEF
nd  595  (18.4%)  patients  in  HF-PEF.  The  LVEF  value  was
nknown  in  248  patients  (7.7%)  out  of  the  whole  ODIN  popu-
ation.  The  percentage  of  men  was  higher  in  case  of  reduced
VEF  (75.8%  in  HF-REF,  65.2%  in  HF-BEF  and  55.1%  in  HF-PEF;
 <  0.001).  Mean  age  was  higher  in  case  of  preserved  LVEF
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Table  1  Main  patient  characteristics  according  to  age-deﬁned  and  LVEF-deﬁned  groups.
Age 1 Age 2 Age 3 Age 4 P HF-REF HF-BEF HF-PEF P
Women 26 24 30 44 < 0.001 24 35 45 < 0.001
Age (years) 50.2 ± 8.1 64.9 ± 3.0 75.3 ± 2.9 84.7 ± 3.3 < 0.001 65.6 ± 13.9 68.6 ± 14.2 72.3 ± 12.9 < 0.001
Ischaemic heart
disease
38  48 53 50 < 0.001 52 45 34 < 0.001
DCM 37 28 19 12 < 0.001 32 20 11 < 0.001
Hypertension 36 56 65 67 < 0.001 49 57 71 < 0.001
Diabetes 25 39 43 27 < 0.001 31 35 38 0.006
Hypercholes-
terolaemia
46 58 58 43 < 0.001 53 52 47 ns
Smoking 55 44 34 22 < 0.001 45 39 31 < 0.001
NYHA III/IV class 13.5 17.0 22.7 36.5 < 0.001 22.5 19.1 17.2 0.010
LVEF (%) 36.0 ± 12.3 38.3 ± 13.9 41.2 ± 14.7 44.8 ± 14.7 < 0.001 31.1 ± 7.4 47.2 ± 2.3 62.0 ± 7.0 < 0.001
Atrial ﬁbrillation 9.3 20.5 36.6 48.9 < 0.001 22.5 30.3 40.7 < 0.001
LBBB 21.8 27.4 26.6 23.7 ns 29.9 17.8 13.8 < 0.001
Biventricular
pacemaker
5.7 11.7 11.2 5.2 < 0.001 11.5 5.4 1.7 < 0.001
ICD 16.8 19.1 11.7 1.7 < 0.001 18.9 3.9 1.3 < 0.001
BMI (%) 27.8 ± 6.2 28.1 ± 5.8 27.6 ± 5.5 25.3 ± 4.2 < 0.001 26.8 ± 5.4 27.8 ± 5.9 28.7 ± 6.3 < 0.001
Serum glucose
(g/L)
1.07 ± 0.43 1.13 ± 0.42 1.13 ± 0.38 1.09 ± 0.42 0.028 1.07 ± 0.38 1.09 ± 0.38 1.16 ± 0.44 0.002
Serum
creatinine
(mg/L)
11.2 ± 5.3 13.1 ± 6.2 13.9 ± 5.8 14.4 ± 6.2 < 0.001 12.8 ±5.7 13.3 ± 7.2 13.3 ± 5.8 ns
Serum
haemoglobin
(g/L)
13.5 ± 1.9 13.1 ± 1.9 12.6 ± 1.8 12.4 ± 1.8 < 0.001 13.1 ± 1.9 12.7 ± 1.9 12.7 ± 1.9 < 0.001
BNP (pg/mL) 415 ± 582 574 ± 874 816 ± 1374 1158 ± 1404 < 0.001 764 ± 1259 565 ± 735 550 ± 708 0.003
NT-BNP (pg/mL) 2370 ± 3831 2875 ± 5149 4115 ± 5420 6047 ± 7003 < 0.001 4323 ± 6058 3803 ± 5697 2504 ± 3986 0.003
Follow-up
deaths
9.4 14.5 25.9 37.4 < 0.001 20.3 22.8 20.5 ns
Data are % or mean ± standard deviation. BMI: body mass index; BNP: B-type natriuretic peptide; DCM: idiopathic dilated cardiomyopa-
thy; ICD: implantable cardiac deﬁbrillator; LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; ns: not signiﬁcant;
NT-BNP: NT-pro-type B natriuretic peptide; NYHA: New York Heart Association.
(
(65.5  ±  13.9  years  in  HF-REF,  68.6  ±  14.2  years  in  HF-BEF  and
72.3  ±  12.9  years  in  HF-PEF;  P  <  0.001).  The  proportion  of
older  patients  (≥  70  years,  Age  3  and  Age  4)  was  higher  in
case  of  borderline  and  preserved  LVEF  (Fig.  1).  Cumulative
survival  curves  showed  that  type  of  CHF  did  not  affect  sur-
vival  (Fig.  2).
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Table  2  Multivariable  Cox  analysis  according  to  age-deﬁned  
treatments.
Variable  Hazard  rat
Age-deﬁned  group  1.46  
LVEF-deﬁned  group  0.80  
Valvular  heart  disease 1.33  
Idiopathic  dilated  cardiomyopathy  0.72  
Beta-blockers  0.76  
ACEIs  or  ARBs 0.60
Loop  diuretics  2.09  
Atrial  ﬁbrillation  1.40  
Serum  haemoglobin  1.00  
Serum  natriuretic  peptides  1.00  
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin recept
fraction.Regarding  aging,  the  three  major  CHF  medications
ACEIs  +  ARBs,  beta-blockers  and  MRAs)  were  prescribed  pro-
ressively  and  signiﬁcantly  less  frequently  as  LVEF  was
ore  preserved  (Fig.  4).  However,  the  use  of  loop  diuret-
cs,  nitrates,  amiodarone  and  anticoagulants  was  inﬂuenced
oorly  or  not  at  all  by  LVEF.  The  prescription  of  the  other
groups,  LVEF-deﬁned  groups,  risk  factors  and  main  drug
io  95%  CI  P
1.33—1.60  <  0.001
0.71—0.89  <  0.001
1.08—1.64  0.007
0.57—0.91  0.006
0.62—0.92  0.006
0.48—0.75 <  0.001
1.51—2.89  <  0.001
1.17—1.67  <  0.001
1.00—1.00  0.009
1.00—1.00  <  0.001
or blocker; CI: conﬁdence interval; LVEF: left ventricular ejection
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Figure 1. A. Distribution of types of chronic heart failure (left
ventricular ejection fraction < 45% [heart failure with reduced ejec-
tion fraction, HF-REF], 45—50% [heart failure with borderline
ejection fraction, HF-BEF] and > 50% [heart failure with preserved
ejection fraction, HF-PEF]), according to age group (< 60 years [Age
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Figure 2. Kaplan-Meier cumulative 2-year survival curve of all-
cause mortality according to (A) age and (B) type of chronic heart
failure. HF-REF: heart failure with reduced ejection fraction; HF-
B
f
s
i
f
(
p
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D], 60 to < 70 years [Age 2], 70 to < 80 years [Age 3], and ≥ 80 years
Age 4]). B. Distribution of age groups according to type of chronic
eart failure.
rugs  was  related  to  aetiology,  depending  on  the  presence  of
educed  or  preserved  CHF;  this  was  as  expected,  given  that
here  is  less  frequent  ischaemic  heart  disease  when  systolic
ardiac  function  is  preserved,  resulting  in  less  frequency  of
rescription  of  statins  and  antiplatelet  therapies;  in  addi-
ion,  systemic  hypertension  is  more  frequently  associated
ith  preserved  ejection  fraction,  resulting  in  a  higher  rate
f  prescription  of  calcium  blockers  (Fig.  4).
The  mean  dosages  of  the  main  prescribed  CHF  drugs  also
emained  ≥  50%  lower  than  those  recommended  for  the
ajority  of  the  drugs  (Table  4).  However,  only  two  drugs  had
 mean  dosage  that  was  signiﬁcantly  different  according  to
he  type  of  CHF:  perindopril  titrated  lower  and  spironolac-
one  higher  in  HF-PEF  than  in  HF-REF  or  HF-BEF  (Table  4).
nteraction between age and type of CHFhen  comparing  prescription  of  medications  in  each  age
roup  according  to  type  of  CHF  (Figs.  5—7),  differences  in
rug  prescription  appeared  to  persist  between  age  groups,
W
l
iEF: heart failure with borderline ejection fraction; HF-PEF: heart
ailure with preserved ejection fraction; ns: not signiﬁcant.
howing  a global  decrease  in  CHF  drug  prescription  accord-
ng  to  maintenance  of  relatively  or  totally  preserved  LVEF
or  all  classes  of  medications,  except  for  calcium  blockers
which  were  prescribed  increasingly  when  LVEF  was  more
reserved)  and  loop  diuretics  (which  were  little  inﬂuenced
y  the  type  of  CHF).
iscussione  assessed  the  effect  of  age  and  type  of  CHF  (deﬁned  by  the
evel  of  LVEF)  on  prescription  of  cardiovascular  medications
n  CHF  in  a  large  French  cohort  of  CHF  patients.  In  routine
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receptor blocker; BB: beta-blockers; MRA: mineralocorticoid-receptor an
Table  3  Comparison  of  mean  dosages  (mg/day)  for  the  main
groups.
Age  1 Age  2  
Ramipril  7.1  ±  3.3  7.0  ±  3.1  
Perindopril  5.6  ±  2.5  5.2  ±  2.4  
Bisoprolol  5.8  ±  3.2  5.4  ±  3.3  
Carvedilol  40.0  ±  25.0  36.1  ±  22.6  
Nebivolol  5.6  ±  2.8  5.3  ±  3.2  
Candesartan  15.4  ±  9.8  14.1  ±  9.2  
Spironolactone  27.4  ±  13.1  25.8  ±  11.1  
Furosemide  85  ±  132  101  ±  154  
Data are mean ± standard deviation.
Table  4  Comparison  of  mean  dosages  (mg/day)  for  the  main
groups.
HF-REF  HF-BEF  
Ramipril  6.6  ±  3.3  6.3  ±  3.5  
Perindopril  5.4  ±  2.5  5.2  ±  2.5  
Bisoprolol  5.2  ±  3.2  5.0  ±  3.1  
Carvedilol  34.6  ±  22.3  33.2  ±  24.5  
Nebivolol  4.8  ±  3.0  4.0  ±  2.5  
Candesartan  14.8  ±  9.7  13.2  ±  7.6  
Spironolactone  25.0  ±  10.9  25.5  ±  13.9  
Furosemide  100  ±  150  93  ±  134  
Data are mean ± standard deviation. HF-REF: heart failure with reduced
fraction; HF-PEF: heart failure with preserved ejection fraction; LVEF:
a For the comparison between HF-REF and HR-PEF.s. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin
tagonist.
 prescribed  chronic  heart  failure  drugs  according  to  age
Age  3  Age  4  P
6.3  ±  3.2  4.9  ±  3.2  <  0.001
4.9  ±  2.6  4.4  ±  2.3  <  0.001
4.8  ±  3.1  3.8  ±  2.7  <  0.001
30.1  ±  17.3  22.8  ±  16.7  <  0.001
4.3  ±  2.5  3.9  ±  2.7  0.003
14.7  ±  9.3  11.6  ±  7.3  0.024
24.2  ±  11.5  23.7  ±  10.4  0.004
109  ±  165  102  ±  133  0.021
 chronic  heart  failure  drugs  prescribed  according  to  LVEF
HF-PEF  P  Pa
6.9  ±  3.2  ns  (0.274)  ns  (1.000)
4.4  ±  2.2  0.001  <  0.001
5.2  ±  3.4  ns  (0.691)  ns  (1.000)
36.6  ±  21.6  ns  (0.845)  ns  (1.000)
4.5  ±  2.8  ns  (0.318)  ns  (1.000)
13.5  ±  8.8  ns  (0.310)  ns  (0.754)
28.2  ±  13.5  0.021  0.017
100  ±  145  ns  (0.735)  ns  (1.000)
 ejection fraction; HF-BEF: heart failure with borderline ejection
 left ventricular ejection fraction; ns: not signiﬁcant.
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Figure 4. Distribution of cardiovascular classes according to types of chronic heart failure. ACEI: angiotensin-converting enzyme inhibitor;
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s: not signiﬁcant.
linical  practice,  both  older  age  and  preserved  LVEF  were
ssociated  with  a  decrease  in  the  rate  of  prescription  of
ll  major  recommended  CHF  drugs.  A  decrease  in  CHF  drug
rescription  according  to  age  persisted,  regardless  of  the
ype  of  CHF  (represented  by  the  level  of  LVEF).  Long-term
urvival  was  inﬂuenced  by  age  but  not  by  the  type  of  CHF
deﬁned  by  the  level  of  LVEF).
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igure 5. Distribution of cardiovascular classes according to age group
EF). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin rec
ntagonist; ns: not signiﬁcant.lar ejection fraction; MRA: mineralocorticoid-receptor antagonist;
As  already  shown  by  the  OFICA  registry  [17],  patients
ospitalized  for  CHF  in  France  are  often  old  and  a  large
roportion  has  preserved  LVEF.  As  previously  published
13], the  baseline  characteristics  of  the  patients  in  the
DIN  cohort  appear  similar  to  those  in  previous  French  and
estern  European  cohorts  [18—21].  The  percentage  of  pre-
cribed  cardiovascular  medications  was  in  accordance  with
s in patients with heart failure with reduced ejection fraction (HF-
eptor blocker; BB: beta-blockers; MRA: mineralocorticoid-receptor
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Figure 6. Distribution of cardiovascular classes according to age groups in patients with heart failure with borderline ejection fraction (HF-
in rec
t
c
a
lBEF). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotens
antagonist; ns: not signiﬁcant.
European  guidelines  for  the  relevant  period  [11].  Changes  in
therapeutic  recommendations  appeared  in  2012,  after  the
end  of  inclusion  [15].  However,  dosages  of  the  recommended
drugs  remained  lower  than  recommended,  as  previously
reported  [19—21].  While  the  role  of  high  dosage  of  ACEIs
might  be  under  discussion  following  the  ATLAS  results  [22],
large  cohorts  have  shown  that  higher  is  better,  even  in
t
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Figure 7. Distribution of cardiovascular classes according to age groups
PEF). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin rec
antagonist; ns: not signiﬁcant.eptor blocker; BB: beta-blockers; MRA: mineralocorticoid-receptor
he  elderly  [23]. Many  gaps  exist  between  the  population
haracteristics  of  randomized  controlled  trials  (younger
ge,  fewer  co-morbid  conditions)  and  real-life  CHF  popu-
ations,  as  in  registries.  Applying  the  results  of  randomized
rials  to  the  general  population  can  lead  to  an  increase  in
dverse  effects,  as  shown  by  the  epidemic  of  hyperkalaemia
escribed  after  publication  of  the  RALES  study  [24].
 in patients with heart failure with preserved ejection fraction (HF-
eptor blocker; BB: beta-blockers; MRA: mineralocorticoid-receptor
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Our  study  has  conﬁrmed  the  improvement  in  the  per-
entage  of  major  CHF  drugs  prescribed  that  was  seen  in
revious  international  publications  [21,25]  from  national
rench  registries  [20,21,26];  this  is  probably  related  to
 better  knowledge  of  international  guidelines  and  the
esults  of  large  therapeutic  trials.  Nevertheless,  we  found  a
arked  increase  in  the  rate  of  prescription  of  beta-blockers
ompared  with  the  results  of  the  IMPACT-RECO  survey  (65
o  81%)  [20],  while  prescription  rates  for  blockers  of  the
enin-angiotensin  system  (ACEIs,  ARBs  or  MRAs)  remained
nchanged.  These  ﬁndings  show  that  the  cardiologists  in
harge  of  CHF  well  understand  the  major  role  of  beta-
lockade  in  CHF,  even  if,  in  2013,  ivabradine  might  be
nitiated  too  often  prior  to  optimization  of  beta-blockade
itration,  based  on  the  results  of  the  SHIFT  trial  [27].
Although  prescription  rates  of  recommended  CHF  drugs
ncreased,  mean  doses  of  the  major  recommended  drugs
emained  dramatically  low,  as  is  always  found  in  the
ajority  of  registries  [28—30].  As  already  shown  by  the
MPACT-RECO  survey  [20,21],  age  is  a  most  important  limiting
actor  for  the  prescription  of  CHF  therapy.  Older  patients
eceived  fewer  ACEIs/ARBs,  beta-blockers  and  MRAs,  but
ore  diuretics.  These  results  are  in  agreement  with  previous
eports  [31].  However,  age  is  too  often  a  poor  justiﬁcation
or  not  introducing  recommended  CHF  treatments,  even  if
he  presence  of  renal  failure  or  a  history  of  asthma  or  chronic
bstructive  pulmonary  disease  remain  prognostic  factors  for
ower  prescription  rates,  particularly  in  relation  to  age  [20].
Despite  the  heterogeneity  of  HF-PEF,  prescription  rates
emained  similar  to  those  for  HF-REF,  with  age  having  a sim-
lar  effect,  even  if  the  rates  were  signiﬁcantly  lower  for  the
ajor  recommended  drugs  in  general.  These  data  have  been
lready  shown  in  European  registries  [32]  and  in  France  [28]
ith  drugs  having  a  similar  impact.  As  guidelines  regarding
F-PEF  are  scarce,  the  only  efﬁcient  treatment  applied  in
ractice  was  the  use  of  the  lowest  diuretic  dose  necessary
o  relieve  ﬂuid  overload,  salt  restriction  and  blood  pres-
ure  control.  However,  in  HF-PEF,  the  absence  of  impact
f  medical  treatment  on  survival  curves  over  the  last  three
ecades  [33],  as  well  as  the  negativity  of  all  randomized
rials  [34,35],  could  suggest  that  applying  recommendations
or  HF-REF  to  HF-PEF  is  not  justiﬁed.  Our  study  showed  that
ardiologists  did  not  know  which  strategy  to  use  in  case  of
HF  due  to  HF-PEF.
tudy limitations
his  study  is  subject  to  the  usual  limitations  of  observa-
ional  studies.  The  most  important  potential  bias  was  the
ack  of  randomization.  We  chose  an  observational  registry
erformed  in  routine  clinical  practice  by  centres  particularly
nterested  in  CHF  management  and  trained  in  therapeutic
atient  education.  Therefore,  it  did  not  provide  an  insight
nto  the  management  of  CHF  by  general  practitioners.
ational  I-CARE  centre  participation  was  around  60%.  Some
entres  were  unable  to  develop  therapeutic  patient  educa-
ion  for  the  usual  ﬁnancial,  human  and  material  reasons  [14]
nd  decided  not  to  participate  in  the  study.  Only  12  (19.7%)
nstitutions  (rehabilitation  centres  and  CHF  networks)
sed  multidisciplinary  teams,  permitting  more  frequent
nd  prolonged  contact  between  patients  and  healthcare
roviders.
(
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onclusion
n  CHF,  and  despite  management  by  cardiologists  particu-
arly  interested  by  CHF  and  speciﬁcally  trained  to  deliver
herapeutic  patient  education,  medical  prescription  sub-
tantially  differed  from  guidelines.  Age  and  type  of  CHF
reduced  versus  preserved)  appeared  to  be  important  fac-
ors  in  lack  of  adherence  to  guidelines.  However,  only  age
nﬂuenced  mortality;  the  type  of  CHF  (deﬁned  by  the  level
f  LVEF)  did  not  have  any  effect  on  survival.
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